V. Lawlis Biography and Net Worth



Bryan Lawlis, Ph.D., joined our Board in June 2007. From August 2011 to September 2017 he served as the President and Chief Executive Officer of Itero Biopharmaceuticals, LLC, a private holding company that held the assets of Itero Biopharmaceuticals, Inc., a private biotechnology company. Dr. Lawlis co-founded and served as President and Chief Executive Officer of Itero Biopharmaceuticals, Inc. from 2006 until it discontinued operations in August 2011. Dr. Lawlis served as President and Chief Executive Officer of Aradigm Corporation, a pharmaceutical company, from August 2004 to August 2006, and served on its board from February 2005 to August 2006, continuing in both capacities until August 2006. Dr. Lawlis previously served as Aradigm’s President and Chief Operating Officer from June 2003 to August 2004 and its Chief Operating Officer from November 2001 to June 2003. Prior to his time at Aradigm, Dr. Lawlis co-founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, and served as its President and Chief Executive Officer from 1996 to 1999, and as its Chairman from 1999 to 2001, when it was sold to Diosynth RTP, Inc., a division of Akzo Nobel, NV. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc., a biotechnology company, and Genentech, Inc. His last position at Genentech, Inc. was Vice President of Process Sciences. Dr. Lawlis serves on the boards of two public biopharmaceutical companies, Aeglea BioTherapeutics, Inc. and Geron Corporation. He previously served on the board of Sutro Biopharma, Inc., a public biopharmaceutical company, from January 2004 until June 2019. Dr. Lawlis holds board positions at two private companies, AbSci, LLC and Reform Biologics LLC, and he serves as an advisor to Phoenix Venture Partners, a venture capital firm focusing on manufacturing technologies and material sciences technologies. He also serves on the Manufacturing Advisory Board of Allakos, Inc. and he advises W.L. Gore and Associates. Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin, and a Ph.D. in Biochemistry from Washington State University.

What is V. Bryan Lawlis' net worth?

The estimated net worth of V. Bryan Lawlis is at least $2.53 million as of April 3rd, 2023. Mr. Lawlis owns 28,950 shares of BioMarin Pharmaceutical stock worth more than $2,527,914 as of March 28th. This net worth evaluation does not reflect any other investments that Mr. Lawlis may own. Learn More about V. Bryan Lawlis' net worth.

How do I contact V. Bryan Lawlis?

The corporate mailing address for Mr. Lawlis and other BioMarin Pharmaceutical executives is 770 Lindaro Street, San Rafael CA, 94901. BioMarin Pharmaceutical can also be reached via phone at (415) 506-6700 and via email at [email protected]. Learn More on V. Bryan Lawlis' contact information.

Has V. Bryan Lawlis been buying or selling shares of BioMarin Pharmaceutical?

V. Bryan Lawlis has not been actively trading shares of BioMarin Pharmaceutical during the past quarter. Most recently, V Bryan Lawlis sold 8,500 shares of the business's stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $97.09, for a transaction totalling $825,265.00. Following the completion of the sale, the director now directly owns 28,950 shares of the company's stock, valued at $2,810,755.50. Learn More on V. Bryan Lawlis' trading history.

Who are BioMarin Pharmaceutical's active insiders?

BioMarin Pharmaceutical's insider roster includes Jeffrey Ajer (EVP), Mark Alles (Director), Jean Bienaime (CEO), George Davis (EVP), Willard Dere (Director), Henry Fuchs (Insider), Michael Grey (Director), Charles Guyer (EVP), V. Lawlis (Director), Richard Meier (Director), Brian Mueller (CFO), David Pyott (Director), and Dennis Slamon (Director). Learn More on BioMarin Pharmaceutical's active insiders.

Are insiders buying or selling shares of BioMarin Pharmaceutical?

In the last twelve months, insiders at the biotechnology company sold shares 16 times. They sold a total of 180,605 shares worth more than $16,591,040.58. The most recent insider tranaction occured on March, 5th when insider Henry J Fuchs sold 35,341 shares worth more than $3,010,346.38. Insiders at BioMarin Pharmaceutical own 1.8% of the company. Learn More about insider trades at BioMarin Pharmaceutical.

Information on this page was last updated on 3/5/2024.

V. Bryan Lawlis Insider Trading History at BioMarin Pharmaceutical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/3/2023Sell8,500$97.09$825,265.0028,950View SEC Filing Icon  
4/14/2022Sell4,250$83.66$355,555.0023,970View SEC Filing Icon  
1/14/2022Sell4,250$87.61$372,342.50View SEC Filing Icon  
6/5/2020Sell4,430$107.46$476,047.8018,850View SEC Filing Icon  
3/17/2020Sell3,750$75.39$282,712.5018,980View SEC Filing Icon  
12/17/2019Sell3,750$83.36$312,600.0027,340View SEC Filing Icon  
9/17/2019Sell3,750$74.47$279,262.5027,340View SEC Filing Icon  
6/17/2019Sell3,750$81.08$304,050.0027,340View SEC Filing Icon  
3/27/2019Sell2,150$89.76$192,984.0021,310View SEC Filing Icon  
12/27/2018Sell2,150$82.53$177,439.5021,310View SEC Filing Icon  
9/27/2018Sell2,150$97.93$210,549.5021,310View SEC Filing Icon  
6/27/2018Sell2,150$93.52$201,068.0021,310View SEC Filing Icon  
4/17/2018Sell3,750$85.00$318,750.0018,610View SEC Filing Icon  
1/2/2018Sell3,750$88.84$333,150.00View SEC Filing Icon  
9/15/2017Sell3,750$91.26$342,225.0019,660View SEC Filing Icon  
6/16/2017Sell3,750$90.00$337,500.0019,660View SEC Filing Icon  
3/1/2017Sell7,500$95.00$712,500.0021,360View SEC Filing Icon  
7/27/2016Sell1,100$95.39$104,929.0014,960View SEC Filing Icon  
7/22/2016Sell6,400$95.01$608,064.0020,260View SEC Filing Icon  
6/20/2016Sell550$82.77$45,523.5013,860View SEC Filing Icon  
11/16/2015Sell8,550$106.90$913,995.0011,850View SEC Filing Icon  
5/16/2014Sell1,700$56.87$96,679.009,700View SEC Filing Icon  
See Full Table

V. Bryan Lawlis Buying and Selling Activity at BioMarin Pharmaceutical

This chart shows V Bryan Lawlis's buying and selling at BioMarin Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioMarin Pharmaceutical Company Overview

BioMarin Pharmaceutical logo
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Read More

Today's Range

Now: $87.32
Low: $86.65
High: $88.66

50 Day Range

MA: $88.22
Low: $83.81
High: $94.04

2 Week Range

Now: $87.32
Low: $76.02
High: $100.38

Volume

535,349 shs

Average Volume

1,319,420 shs

Market Capitalization

$16.48 billion

P/E Ratio

99.23

Dividend Yield

N/A

Beta

0.31